Gritstone Bio PE Ratio 2017-2022 | GRTS
Current and historical p/e ratio for Gritstone Bio (GRTS) from 2017 to 2022. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Gritstone Bio PE ratio as of May 24, 2022 is 0.00.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Gritstone Bio PE Ratio Historical Data |
| Date |
Stock Price |
TTM Net EPS |
PE Ratio |
| 2022-05-25 |
1.77 |
|
0.00 |
| 2022-03-31 |
4.12 |
$-1.05 |
0.00 |
| 2021-12-31 |
12.86 |
$-0.95 |
0.00 |
| 2021-09-30 |
10.80 |
$-1.28 |
0.00 |
| 2021-06-30 |
9.13 |
$-1.61 |
0.00 |
| 2021-03-31 |
9.43 |
$-1.97 |
0.00 |
| 2020-12-31 |
3.94 |
$-2.78 |
0.00 |
| 2020-09-30 |
2.65 |
$-2.86 |
0.00 |
| 2020-06-30 |
6.64 |
$-2.94 |
0.00 |
| 2020-03-31 |
5.82 |
$-2.88 |
0.00 |
| 2019-12-31 |
8.97 |
$-2.79 |
0.00 |
| 2019-09-30 |
8.64 |
$-2.63 |
0.00 |
| 2019-06-30 |
11.14 |
$-9.46 |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.131B |
$0.048B |
|
Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The company has built its tumor-specific immunotherapy approach on two key pillars - first, a proprietary machine learning-based platform, Gritstone EDGE(TM), which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patient?s tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patients? TSNA to drive the patient?s immune system to attack and destroy tumors.
|
